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ABSTRACT
Clostridium difficile infection is the most prevalent health care-associated infection. Treatment relies on antimicrobial therapy with
mounting evidence supporting fecal microbiota transplant (FMT) in refractory cases. Cohort studies have documented the safety of
FMT in immunocompromised patients. However, the safety of FMT in patients with critically low (,500/mL) absolute neutrophil
count is unknown. Currently, in severely immunocompromised bone marrow or solid organ transplant recipients, FMT is delayed
until normalization of absolute neutrophil count. We present a patient with absolute neutropenia in whom sequential FMTs were
safely and successfully administered, resulting in cure of fulminant C. difficile infection.
INTRODUCTION
Clostridium difficile infection (CDI) has become the most prevalent health care-associated infection with an attributable cost
estimated at over $6 billion and mortality of 29,300 patients per year.1,2 Much of the costs, morbidity, and mortality are associated
with recurrent and severe or fulminant CDI. Patients who are immunocompromised, particularly those after bone marrow
transplant, are at increased risk of developing both recurrent and severe CDI often refractory to antimicrobial therapy.3 High-quality
evidence supports the safety and efficacy of fecal microbiota transplant (FMT) in nonresponders and patients with severe or
fulminant CDI.4–7 A protocol consisting of sequential FMTs administered in rapid cycles in combination with vancomycin was
found to be efficacious at our institution for the treatment of refractory severe/fulminant CDI, and its success was echoed in a recent
randomized clinical trial conducted in Italy.8,9
Recent reports suggest FMT is safe and effective in immunocompromised patients for the treatment of C. difficile infection
(CDI).10–12 However, it is not recommended for patients with severe neutropenia.10 Ongoing clinical trials using FMT in bone
marrow transplant recipients postpone FMT until the neutrophil count normalizes.
CASE REPORT
A 56-year-old man with a history of multiple myeloma status postbone marrow transplant with relapse undergoing salvage
chemotherapy (day 4) presented with loose stools, fever of 101.6°F, and hypotension. Laboratory examination showed a white blood
cell count of 1,600/mL (absolute neutrophil count [ANC] of 1,000), creatinine of 0.8 mg/dL, albumin of 2.2 g/L, and lactate of 4.4
mmol/L. Computed tomography imaging showed pancolitis, and he was diagnosed with severe-complicated CDI (Figure 1).
Therapy was initiated with oral vancomycin (125 mg every 6 hours) and intravenous metronidazole (500 mg every 8 hours).
The fever resolved, but the diarrhea continued along with the onset of severe abdominal pain on day 3, at which time a follow-up x-
ray showed progressive colonic dilation consistent with toxicmegacolon (Figure 2). Vancomycin dose was increased to 500mg every
6 hours. Blood counts dropped with an ANC nadir of 10/mL. Given the lack of response to maximum antimicrobial therapy, the
patient was evaluated by our surgery colleagues but deemed not a surgical candidate. After significant discussion of risks and benefits,
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a FMT via flexible sigmoidoscopywas pursued. Colon preparation
was deferred given the patient’s tenuous clinical status and lack of
oral intake. The initial endoscopy showed dense and diffuse
pseudomembranes, and FMT was performed with frozen/
reconstituted stool obtained from the OpenBiome stool bank
(Figure 3). The antimicrobial regimen was continued up to and
after the procedure.
After the first FMT, the patient’s symptoms including diarrhea,
abdominal pain, and abdominal distention persisted, and he also
developed hemodynamic instability. Endoscopic FMTs were re-
peated 4 times in the next 8 days. Subsequently, a nasoduodenal
tube was placed, and FMT was repeated with 250 cc of frozen/
reconstituted stool on 4 more occasions within 10 days. Initial
decisions regarding recurrent FMTs every 1–3 days were based on
persistent pseudomembranes along with the clinical status
including diarrhea and abdominal distention. Subsequent recurrent
FMTs administered via the nasoduodenal tube were based on the
patient’s clinical status (ie, abdominal pain and diarrhea). This is
similar to our previously reported protocol for severe and severe-
complicated CDI in which FMT was repeated at 5 days intervals.7
However, the protocol was adapted to this patient’s specific clinical
scenario in which FMTs were pursed more frequently and anti-
biotics were continued given profound immunosuppression.
His clinical picture improved with decreased abdominal pain and
diarrhea, and a diagnostic sigmoidoscopy showed only patchy
distribution of pseudomembranes on day 22 (Figure 4). He was
discharged on tapering doses of oral vancomycin.
Immediately after completionof the vancomycin course at 6weeks
posthospital discharge, his profuse diarrhea and abdominal pain
recurred and stool C. difficile was positive by polymerase chain
reaction. The patient was readmitted, and colonoscopic FMT was
performed at which time diffuse pseudomembranes were again
noted. Fidaxomicin 200 mg twice daily was started, and repeat
FMT was performed 3 days later. The diarrhea resolved, and he
was discharged the next daywith a plan for completing a course of
fidaxomicin. In total, he received 11 FMTs, of which 7 were ad-
ministered colonoscopically on days 2, 7, 8, 11, 12, 45, and 48 after
the initial presentation and 4 via a nasojejunal tube on days 13, 14,
21, and 24. He did not experience recurrence of CDI during the 6
months of follow-up. Importantly, no procedure-related or in-
fectious complications were noted.
DISCUSSION
Our case illustrates that FMT can be safely administered in
a patient with critically lowANC.Our patient underwent a total
of 11 FMTs, of which 2 were administered while the patient had
Figure 1. Computed tomography showing pancolitis.
Figure 2. X-ray showing progressive colonic dilation consistent with
toxic megacolon.
Figure 3. Initial endoscopy showing dense and diffuse
pseudomembranes.
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an ANC ,500/mL without any adverse events. It may not be
necessary to delay FMT for safety reasons in critically ill patients
until the neutrophil count recovery is achieved.
This case also points to the potential of FMT to cure severe or
fulminant CDI in this high-risk patient population. Given the
severely immunocompromised state, severe/fulminant CDI, and
the need for continuation of non-CDI antibiotics for other infec-
tions, these patients will likely require several or serial FMTs with
or without coadministration of anti-CDI antimicrobials for cure.
Evaluation by a multidisciplinary team including infectious
disease specialists, gastroenterologists, and surgeons is key to
determine the best management. A detailed discussion of risks/
benefits, potential adverse events, and alternative therapies with
the patient and family along with obtaining an informed consent
is imperative. The high likelihood of needing multiple FMTs to
achieve cure should be considered and planned for.
As illustrated in the presented case, FMT, a potentially life-saving
therapy for severe and fulminant CDI, may be administered
safely without delay in patients with critical neutropenia. Mul-
tiple FMTs will likely be needed for cure in this case scenario.
Although this is a single case, it does provide anecdotal evidence
regarding safety and efficacy in this population of patients who
often have few options because they are not considered surgical
candidates.We recommend that in severely neutropenic patients
with severe or fulminant CDI refractory to conventional therapy,
FMT should be considered without delay.
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Figure 4. Sigmoidoscopy showing patchy distribution of pseudo-
membranes on day 22, consistent with improvement.
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